Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2023.05.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
Medicine (Baltimore)
December 2023
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Despite the demonstrated advantages of angiotensin receptor/neprilysin inhibitors in the management of heart failure, the pivotal Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial, which explored this class of medications, did not include individuals from Saudi Arabia. Recognizing that different nations and ethnic groups may exhibit unique characteristics, this study aimed to compare the demographics and outcomes of patients in Saudi Arabia who received sacubitril/valsartan (Sac/Val) with those enrolled in the PARADIGM-HF trial. In this retrospective, multicenter cohort study, we included all adult patients diagnosed with heart failure with reduced ejection fraction (HFrEF) within a tertiary healthcare system in Saudi Arabia between January 2018 and December 2021 and were initiated on Sac/Val.
View Article and Find Full Text PDFAngiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Curr Probl Cardiol
January 2024
Division of Hospital Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Article Synopsis
- Current research on sacubitril/valsartan's effects on heart failure with preserved ejection fraction (HFpEF) is inconclusive, prompting further investigation into its efficacy.
- An analysis of four trials with over 8,000 participants revealed that sacubitril/valsartan significantly decreases NT-proBNP levels and improves the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, indicating improved quality of life.
- While there were no significant changes in hospitalizations or mortality rates, sacubitril/valsartan was generally safe and showed a reduced risk of kidney function decline compared to standard treatments.
Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
J Am Coll Cardiol
July 2023
Center of Advanced Heart Disease, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
J Am Coll Cardiol
July 2023
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- U.S. guidelines suggest considering sacubitril/valsartan for chronic heart failure patients with a mildly reduced or preserved ejection fraction (EF), but its safety and effectiveness after a worsening heart failure event in patients with EF >40% was unclear.
- The PARAGLIDE-HF trial compared sacubitril/valsartan to valsartan in patients with EF >40% who were enrolled within 30 days post-worsening heart failure, measuring the change in NT-proBNP levels as the primary endpoint.
- Results showed that sacubitril/valsartan significantly reduced NT-proBNP levels and had some clinical benefits, although it increased cases of symptomatic hypotension; a greater treatment effect was observed in
Renal Safety of de Novo Angiotensin-Neprilysin Inhibition in Older Adults: Insights From a Population-Based Analysis.
J Card Fail
February 2023
Division of Cardiology, University of British Columbia, Vancouver, Canada.. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!